Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Authors
Keywords
-
Journal
BMJ-British Medical Journal
Volume -, Issue -, Pages n156
Publisher
BMJ
Online
2021-02-25
DOI
10.1136/bmj.n156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future
- (2018) Jeffrey Cummings et al. JOURNAL OF ALZHEIMERS DISEASE
- Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
- (2018) Julia R. Clarke et al. JOURNAL OF ALZHEIMERS DISEASE
- Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
- (2018) Pierrick Bourgeat et al. NEUROIMAGE
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
- (2015) Steve Balsis et al. CLINICAL NEUROPSYCHOLOGIST
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Instrumental variable methods for causal inference
- (2014) Michael Baiocchi et al. STATISTICS IN MEDICINE
- Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
- (2014) Lars Lannfelt et al. Alzheimers Research & Therapy
- Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
- (2012) Kevin Mullane et al. BIOCHEMICAL PHARMACOLOGY
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
- (2012) Bruno P Imbimbo et al. Expert Review of Clinical Immunology
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
- (2012) Peter T. Nelson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Resolving controversies on the path to Alzheimer's therapeutics
- (2011) Dennis J Selkoe NATURE MEDICINE
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- PET imaging of amyloid deposition in patients with mild cognitive impairment
- (2007) Anton Forsberg et al. NEUROBIOLOGY OF AGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now